<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TRAIN" NEWID="8894" OLDID="14415" TOPICS="NO">
<DATE>24-MAR-1987 13:13:31.58</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 
   F
   f1868 reute
d f BC-RIBI-&lt;RIBI&gt;-SIGNS-PAC   03-24 0107</UNKNOWN>
<TEXT> 
<TITLE>RIBI &lt;RIBI&gt; SIGNS PACT WITH TRAVENOL &lt;BAX&gt;</TITLE>
<DATELINE>    HAMILTON, Montana, March 24 - </DATELINE><BODY>Ribi ImmunoChem Research Inc
said Baxter Travenol Laboratories Inc's Travenol Laboratories
Inc unit will evaluate whether one of its products can be used
to prevent infectious disease.
    Under an agreement, Ribi said Travenol will conduct studies
with the product, monophosphoryl lipid A, and will have the
option to pursue a woldwide license for the product.
    Ribi said the product is used in combination with other
agents in experimental treatments to boost the function of the
immune system in patients suffering from malignant melanoma and
other cancers.

 Reuter
 </BODY></TEXT>
</REUTERS>